Education
About Us
Working with TipRanks
Follow Us
Ibio Inc (IBIO)
NASDAQ:IBIO
IBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.40 - $6.89
Previous CloseN/A
Volume55.53K
Average Volume (3M)756.96K
Market Cap
$31.85M
Enterprise Value$19.51M
Total Cash (Recent Filing)$1.49M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 19, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding9,874,676
10 Day Avg. Volume498,445
30 Day Avg. Volume756,959
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)121.92
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit86.71
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$6.00Price Target Upside297.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Ibio News
PremiumCompany Announcements
iBio Highlights Advancements in Obesity Antibody Programs
PremiumCompany Announcements
iBio Reveals Promising Study Results for IBIO-600
PremiumCompany Announcements
iBio, Inc. Advances in Therapeutics and Leadership
PremiumCompany Announcements
iBio Announces Transfer to Nasdaq Capital Market---
Ownership Overview
2.57% Insiders
1.64% Mutual Funds
24.43% Other Institutional Investors
70.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $1.40 and its highest was $6.89 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $31.85M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is May 19, 2025 which is in 40 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Feb 10, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.02.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.32.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 9,874,676 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went down -7.31%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
---
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (297.35% Upside)
$6.00 (297.35% Upside)
Blogger Sentiment
Bearish
IBIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $655.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.43%
12-Months-Change
Fundamentals
Return on Equity
-123.28%
Trailing 12-Months
Asset Growth
-36.23%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
---
IBIO Stock 12 Month Forecast
Average Price Target
$6.00
▲(297.35% Upside)
Technical Analysis
Best Analysts Covering IBIO
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-37.05%
reiterated a buy rating 10 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.05% per trade.
---